News

Pfizer Partners with LianBio to Develop Pharmaceutical Products in China

November 19, 2020

Under the terms of the agreement, Pfizer will provide $70 million toward in-licensing and co-development.

The University of Birmingham Formulates Nasal Spray to Protect Against COVID-19

November 19, 2020

Researchers concluded that the nasal spray should catch and coat the virus inside the nose, preventing it from spreading throughout the body, and it is then removed by nose-blowing or swallowing.

Roquette Launches New Vegetarian Softgel Capsule Formulations

November 19, 2020

The first of its kind, Lycagel is made up of pea starch technology.

Watson-Marlow Reveals Plans for New Facility in Cork, Ireland

November 19, 2020

Watson-Marlow Limited Ireland has revealed plans for a new ISO 14644-1 Class 7 cleanroom to be added to the company’s existing site in Cork, Ireland.

Johnson & Johnson Starts Second Global Phase III Clinical Trial of Janssen COVID-19 Vaccine

November 19, 2020

A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735 has been initiated by Johnson & Johnson.

CordenPharma Expands Non-GMP Solid-Phase Peptide Synthesis Manufacturing Capacity

November 19, 2020

CordenPharma has announced the expansion of its non-GMP SPPS manufacturing capacity at its Centre of Excellence for Peptide Process Development and non-GMP manufacturing in Frankfurt, Germany.

Catalent Completes Acquisition of Bone Therapeutics’ Cell Therapy Manufacturing Subsidiary

November 19, 2020

Bone Therapeutics has reported the completion of Catalent’s acquisition of Skeletal Cell Therapy Support SA (SCTS)—Bone Therapeutics’ cell therapy manufacturing subsidiary.

Eisai Invests in UK Manufacturing Operations

November 19, 2020

Eisai has announced an expansion of its manufacturing operations at its Hatfield production plant in the United Kingdom to meet global demand.

Interim Results Show Strong Immune Responses and Better Tolerability in Older Adults for AZD1222

November 19, 2020

Interim results of AZD1222 trial have demonstrated lower reactogenicity in older adults, and strong immune responses across all adult age groups.

Almac Group Receives Award from COVID-19 Therapeutics Accelerator to Produce Remdesivir

November 19, 2020

Almac Sciences has been granted an award by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.